December 22nd 2022EP. 1: MAIA Trial Overview
Saad Usmani, MD, MBA, FACP, discusses the unmet needs for multiple myeloma patients and the health-related quality of life (HRQoL) data and key takeaways from the MAIA trial presented at ASH 2022.
January 17th 2023EP. 2: Quality of Life in Multiple Myeloma Patients
Saad Usmani, MD, MBA, FACP, explores the burden of multiple myeloma on patient health-related quality of life [HRQoL] and why HRQoL results of clinical trials should be considered when making treatment decisions for this disease.
January 24th 2023EP. 3: GRIFFIN Trial Overview
Saad Usmani, MD, MBA, FACP, discusses the health-related quality of life data from the GRIFFIN trial presented at ASH 2022 and reviews his key takeaways, including his thoughts on how health care decision-makers should act on these results.
January 31st 2023EP. 4: GEM-CESAR Trial Overview
Saad Usmani, MD, MBA, FACP, reviews the GEM-CESAR trial data presented at ASH 2022 on a potential curative strategy for high-risk smoldering myeloma and discusses his treatment strategy for this disease.
February 7th 2023EP. 5: MagnetisMM-1 Trial Overview
Saad Usmani, MD, MBA, FACP, discusses the MagnetisMM-1 trial data evaluating elranatamab in patients with relapsed or refractory multiple myeloma (RRMM) and reviews innovations that are needed to improve the management of RRMM.
